Brii Biosciences Limited announced that the first subject has been dosed in a Phase 1 clinical trial evaluating BRII-297, a long-acting injectable ("LAI"), in development for the treatment of various anxiety and depressive disorders. This Phase 1 study is examining the safety, tolerability and pharmacokinetics of BRII-297 in healthy volunteers in Australia. BRII-297 is a new chemical entity discovered internally.

It acts as a novel gamma-aminobutyric acid A receptor positive allosteric modulator with a LAI formulation, designed to provide rapid, profound and sustained reduction of symptoms, which has the potential to enable therapeutic adherence and convenience for patients living with anxiety and depressive disorders.